Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 21.0

Eligibility Criteria:
Inclusion Criteria:~* Before randomization, a woman must be postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause) and not intending to conceive by any methods~* In the investigator's clinical judgment, participant must be either in good or stable health. Participants may have underlying illnesses such as hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening~* For participants in Cohorts 1 and 2 only: Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the central laboratory normal reference ranges and additionally within the limits of toxicity Grade 2 according to the United States (US) Food and Drug Administration (FDA) toxicity, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator~* From the time of each vaccination through 3 months after each vaccination, participant agrees not to donate blood~* Participant must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study~Exclusion Criteria:~* Per serology testing in Cohorts 1 and 2 and per medical history in Cohort 3: Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively~* Per serology testing in Cohorts 1 and 2 and per medical history in Cohort 3: Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection~* Participant has had major psychiatric illness and/or drug or alcohol abuse which in the investigator's opinion would compromise the participant's safety and/or compliance with the study procedures~* Participant has a known allergy, or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine components (including any of the constituents of the study vaccine)~* Participant has received respiratory syncytial virus (RSV) vaccine in a previous RSV vaccine study at any time prior to randomization

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort (C)1 Group (G)1: Placebo for RSV preF Protein (Type: PLACEBO_COMPARATOR): Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
- C1 G2: RSV preF Protein (Type: EXPERIMENTAL): Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
- C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein (Type: PLACEBO_COMPARATOR): Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
- C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 5\*10\^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
- C1 G5: RSV preF Protein (Type: EXPERIMENTAL): Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
- C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein (Type: PLACEBO_COMPARATOR): Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
- C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 5\*10\^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
- C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein (Type: PLACEBO_COMPARATOR): Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
- C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
- C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo (Type: EXPERIMENTAL): Participants will receive separate intramuscular injections of 1\*10\^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
- C2 G11: Ad26.RSV.preF and Placebo (Type: EXPERIMENTAL): Participants will receive intramuscular injection of 1\*10\^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
- C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 5\*10\^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
- C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
- C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
- C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo (Type: EXPERIMENTAL): Participants will receive intramuscular injection of a mixture of 5\*10\^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
- C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo (Type: EXPERIMENTAL): Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1\*10\^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.
- C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo (Type: EXPERIMENTAL): Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.
- C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein (Type: PLACEBO_COMPARATOR): Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.
- C3 G19: Selected Regimen (SR) (Type: EXPERIMENTAL): If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.
- C3 G20: SR + Placebo for SR (Type: EXPERIMENTAL): If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and Month 24, and a placebo at Month 12. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a placebo at Month 12.
- C3 G21: Placebo for SR (Type: PLACEBO_COMPARATOR): If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).